BR9916549A - Composição farmacêutica, vacina, proteìna, e, método para a prevenção ou tratamento de leishmaniose em um humano ou animal - Google Patents

Composição farmacêutica, vacina, proteìna, e, método para a prevenção ou tratamento de leishmaniose em um humano ou animal

Info

Publication number
BR9916549A
BR9916549A BR9916549-0A BR9916549A BR9916549A BR 9916549 A BR9916549 A BR 9916549A BR 9916549 A BR9916549 A BR 9916549A BR 9916549 A BR9916549 A BR 9916549A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
leishmaniasis
animal
prevention
human
Prior art date
Application number
BR9916549-0A
Other languages
English (en)
Other versions
BRPI9916549B1 (pt
BRPI9916549B8 (pt
Inventor
Carlos Bedate Alonso
Original Assignee
Leti Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2256124A external-priority patent/CA2256124C/en
Application filed by Leti Lab filed Critical Leti Lab
Publication of BR9916549A publication Critical patent/BR9916549A/pt
Publication of BRPI9916549B1 publication Critical patent/BRPI9916549B1/pt
Publication of BRPI9916549B8 publication Critical patent/BRPI9916549B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, VACINA, PROTEìNA, E, MéTODO PARA A PREVENçãO OU TRATAMENTO DE LEISHMANIOSE EM UM HUMANO OU ANIMAL". A presente invenção se refere a uma composição farmacêutica para a prevenção e tratamento, humano ou animal, de Leishmaniose. A composição farmacêutica contém a proteína Quimera Q, que é o produto de um gene quimérico codificando a determinação antigênica de quatro proteínas de Leishmaniose infantum.
BRPI9916549A 1998-12-23 1999-12-23 Composição farmacêutica, proteína, polinucleotídeo BRPI9916549B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11382598P 1998-12-23 1998-12-23
US60/113,825 1998-12-23
CA2256124A CA2256124C (en) 1998-12-23 1998-12-23 Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
CA2,256,124 1998-12-23
PCT/EP1999/010441 WO2000039298A1 (en) 1998-12-23 1999-12-23 Chimeric gene encoding the antigenic determinants of four proteins of l. infantum

Publications (3)

Publication Number Publication Date
BR9916549A true BR9916549A (pt) 2005-01-04
BRPI9916549B1 BRPI9916549B1 (pt) 2018-10-02
BRPI9916549B8 BRPI9916549B8 (pt) 2022-08-30

Family

ID=25680668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9916549A BRPI9916549B8 (pt) 1998-12-23 1999-12-23 Composição farmacêutica, proteína, polinucleotídeo

Country Status (22)

Country Link
EP (1) EP1141305B1 (pt)
CN (1) CN1158387C (pt)
AT (2) ATE429498T1 (pt)
AU (1) AU759316B2 (pt)
BE (1) BE2016C049I2 (pt)
BG (1) BG65569B1 (pt)
BR (1) BRPI9916549B8 (pt)
CY (3) CY1105331T1 (pt)
CZ (1) CZ20012360A3 (pt)
DE (2) DE69931518T2 (pt)
DK (1) DK1141305T3 (pt)
ES (2) ES2326174T3 (pt)
HR (1) HRP20010554A2 (pt)
HU (1) HUP0104743A3 (pt)
IL (2) IL143956A0 (pt)
LU (1) LU93259I2 (pt)
MX (1) MXPA01006548A (pt)
NL (1) NL300830I2 (pt)
PT (2) PT1624063E (pt)
SI (1) SI1624063T1 (pt)
TR (1) TR200102655T2 (pt)
WO (1) WO2000039298A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2169995B1 (es) * 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
WO2006058243A2 (en) * 2004-11-24 2006-06-01 Yale University Leishmania antigens and related compositions and uses
PT2231700E (pt) * 2008-01-18 2014-07-31 Leti S L Unipersonal Lab Vacina que compreende extrato de proteína ribossomal (rpe) e um auxiliar estimulante th1 como opção
WO2011006891A1 (en) * 2009-07-13 2011-01-20 Laboratorios Leti, S.L. Diagnosis of a parasitic disease such as leishmaniasis using ribosomal protein extract (rpe)
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR102019003639A2 (pt) * 2019-02-22 2021-11-16 Fundação Oswaldo Cruz Proteína quimérica, seu método para produção e uso, bem como molécula de ácido nucleico, cassete de expressão, vetor de expressão, célula hospedeira, composição para diagnóstico de leishmaniose, kit de diagnóstico de leishmaniose e método de diagnóstico de leishmaniose in vitro
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703295A1 (en) * 1994-09-26 1996-03-27 Institut Pasteur Vaccine composition comprising recombinant BCG expressing gp 63 fusion protein
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
ES2133236B1 (es) * 1997-06-27 2000-04-16 Leti Lab Gen quimerico formado por las secuencias de dna que codifican los determinantes antigenicos de cuatro proteinas de l. infantum, aplicable para el diagnostico serologico de leishmaniosis canina y proteina obtenida.

Also Published As

Publication number Publication date
DE69931518T2 (de) 2006-12-21
IL143956A0 (en) 2002-04-21
AU759316B2 (en) 2003-04-10
ATE327332T1 (de) 2006-06-15
HUP0104743A3 (en) 2004-10-28
ATE429498T1 (de) 2009-05-15
CN1158387C (zh) 2004-07-21
WO2000039298A1 (en) 2000-07-06
CY2016033I1 (el) 2017-03-15
DE69931518D1 (de) 2006-06-29
CZ20012360A3 (cs) 2001-10-17
CY2016033I2 (el) 2017-03-15
PT1624063E (pt) 2009-06-19
AU2434200A (en) 2000-07-31
CY1105331T1 (el) 2010-03-03
BG105725A (en) 2002-06-28
PT1141305E (pt) 2006-10-31
DE69940793D1 (de) 2009-06-04
NL300830I1 (nl) 2016-09-28
ES2326174T3 (es) 2009-10-02
CY1109221T1 (el) 2014-07-02
BG65569B1 (bg) 2008-12-30
BRPI9916549B1 (pt) 2018-10-02
ES2273519T3 (es) 2007-05-01
MXPA01006548A (es) 2003-03-27
DK1141305T3 (da) 2006-09-25
HUP0104743A2 (hu) 2002-03-28
SI1624063T1 (sl) 2009-08-31
EP1141305A1 (en) 2001-10-10
BRPI9916549B8 (pt) 2022-08-30
HRP20010554A2 (en) 2002-08-31
EP1141305B1 (en) 2006-05-24
IL143956A (en) 2010-11-30
CN1335889A (zh) 2002-02-13
BE2016C049I2 (pt) 2019-03-05
LU93259I2 (fr) 2016-12-06
TR200102655T2 (tr) 2002-04-22
NL300830I2 (nl) 2020-08-31

Similar Documents

Publication Publication Date Title
LU93259I2 (fr) LETIFEND (Protein Q)
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
BR9607889A (pt) Domínio intracelular de protéina her-2/neu para prevenção ou tratamento de malignidades
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
HUP0302304A2 (hu) Tejeredetű csontvédő kompozíciók
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
FR2762993B1 (fr) Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
ES2195555T3 (es) Empleo de composiciones para proporcionar glutamina.
ATE198467T1 (de) Diaromatische propynyl- oder dienylverbindungen
FI972170A (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
DK0845034T3 (da) Peptid med pronociceptive egenskaber
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
BR0309966A (pt) Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos
BRPI9917863B8 (pt) composição farmacêutica que é uma vacina
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
BRPI0418017A (pt) medicamento compreendendo inibidores de pentraxina ptx3 longa
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
ATE27822T1 (de) Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003083472A1 (fr) Methode d'evaluation du risque de maladie parodontale

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/12/2019

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2491, DE 02/10/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B25D Requested change of name of applicant approved

Owner name: LETI PHARMA, S.L.U. (ES)